Epoetin alfa HEXAL® in oncology and haematology patients with chemotherapy induced anaemia. A noninterventional observational study.
- Conditions
- D61.10
- Registration Number
- DRKS00005282
- Lead Sponsor
- Hexal AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 440
1. Diagnosis of solid tumour, malignant lymphoma or multiple myeloma;
2. Tumour therapy with chemotherapy alone or in combination with other therapies;
3.Therapy with Epoetin alfa HEXAL for symptomatic anaemia and a reduction of transfusions is planned for three to six chemotherapy cycles;
4. Written informed consent of patients available covering pro- and retrospective pseudonymised documentation, transmission and analysis of data as well as inspection of data during monitoring.
1. Patient is treated within another study;
2. Tumour therapy consists of radiation alone;
3. Patient suffers from acute leucaemia or chronic myeloproliferative syndrome;
4. Patient suffers from non-treated haemolytic anaemia or from iron, vitamin B12 or folic acid deficiency anaemia not related to the tumour;
5. Patient has participated in the same study earlier;
6. Contraindications to Epoetin alfa HEXAL according to the current summary of product characteristics.
7. Female patients: Pregnancy or breast-feeding.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method